Koyama, Kenichi
Miura, Satoru
Watanabe, Satoshi
Shoji, Satoshi
Koshio, Jun
Hayashi, Yoshiki
Ishikawa, Daisuke
Sato, Ko
Miyabayashi, Takao
Okajima, Masaaki
Ota, Takeshi
Tanaka, Tomohiro
Matsumoto, Naoya
Kuriyama, Hideyuki
Abe, Tetsuya
Nozaki, Koichiro
Ichikawa, Kosuke
Kondo, Rie
Tanaka, Hiroshi
Kikuchi, Toshiaki
Funding for this research was provided by:
AstraZeneca Japan
Article History
Received: 17 November 2021
Accepted: 30 March 2022
First Online: 16 April 2022
Competing interests
: Satoshi Watanabe received honoraria (lecture fee) from AstraZeneca, CHUGAI PHARMACEUTICAL, ONO PHARMACEUTICAL, Eli Lilly Japan, Bristol-Myers, Boehringer Ingelheim, MSD, TAIHO PHARMACEUTICAL, Pfizer, Novartis, and DAIICHI SANKYO. Satoshi Watanabe received research grants from AstraZeneca, Boehringer Ingelheim. Hiroshi Tanaka received honoraria (lecture fee) from AstraZeneca. Toshiaki Kikuchi received honoraria (lecture fee) from Boehringer Ingelheim, AstraZeneca, CHUGAI PHARMACEUTICAL. Toshiaki Kikuchi received a research fund from AstraZeneca. Toshiaki Kikuchi received research grants from SHIONOGI PHARMACEUTICAL, CHUGAI PHARMACEUTICAL, ONO PHARMACEUTICAL, Eli Lilly Japan. Other authors did not have any competing interests.